World’s First Chlamydia Vaccine for Koalas Approved by Scientists

Australia has achieved a significant milestone with the official approval of the world’s first vaccine aimed at protecting endangered koalas from chlamydia. This innovative advancement is expected to bolster conservation efforts for these beloved marsupials.

Crafted by the veterinary medicine division at the University of the Sunshine Coast, this groundbreaking single-dose vaccine targets a disease that accounts for nearly half of all tragic koala fatalities. The implications of this development are profound, considering the disease has been infecting koala populations since the 1990s, reaching alarming rates of infection—up to 100 percent in certain colonies located along Australia’s eastern and southeastern coasts.

With current estimates indicating a population of only 50, 000 to 80, 000 koalas remaining in the wild, conservationists are deeply concerned that parts of the country could witness the extinction of these creatures within a generation. Addressing the health crisis caused by chlamydia is critical to reversing this trend.

Unlike traditional antibiotic treatments, which often harm koalas by depleting essential gut bacteria needed for digesting their primary food source, eucalyptus leaves, the new vaccine promises enduring protection. Over the past decade, trial results have revealed promising outcomes. Notably, a 2024 study highlighted a remarkable reduction in the incidence of symptoms during breeding seasons, as well as a decrease in mortality rates from the disease by at least 65 percent.

Scientists have approved the world’s first vaccine for koala bear chlamydia pic.twitter.com/mb1NsIf6in

— dexerto (@dexerto) September 11, 2025

Vaccine Approval and Future Implementation

The newly approved vaccine is not only effective in reducing infection rates but has also shown potential in halting the progression to clinical disease and, in some circumstances, even reversing symptoms. Its efficacy has been validated through extensive testing involving hundreds of wild koalas, as well as those held in captivity and patients at wildlife hospitals over several generations.

This ambitious project was a collaborative effort, bringing together researchers from the University of Saskatchewan, the University of British Columbia, Dalhousie University, and the International Vaccine Institute, along with substantial support from the Bill and Melinda Gates Foundation, the Morris Animal Foundation, Rane Pharma, and the animal health enterprise Ceva Santé Animale.

Australia Zoo Wildlife Hospital, associated with the family of the late Steve Irwin, significantly contributed to the vaccine trials. Conservationist Terri Irwin noted, “These trials involved vaccinating koalas in real-world conditions, enabling researchers to gather valuable data on the vaccine’s potential benefits.”

Looking ahead, the team is set to commence the vaccine rollout in January 2026, focusing on wildlife hospitals and the populations that are most vulnerable. While the plan aims to provide the vaccine at no cost, securing additional funding and donations will be essential to ensure comprehensive distribution.

Although the approval of this vaccine is a monumental achievement, researchers emphasize that other pressing threats to koalas, such as habitat destruction, climate change, and wildfires, must also be addressed to secure the long-term survival of the species.

Source & Images